Veracyte's genomic test identifies high-risk breast cancer patients who can safely skip chemotherapy, enhancing personalized treatment options.

Karen Bonham was part of successful trial for genomic test that determines which women with breast cancer can safely avoid chemotherapy

Trial suggests patients with a low test score could be treated with hormone therapy alone with near-identical outcomes

Doctors said the test shows people with certain forms of the disease can safely avoid chemotherapy

Veracyte's genomic test identifies high-risk breast cancer patients who can safely skip chemotherapy, enhancing personalized treatment options.

A DNA‑based test of the tumour can help two‑thirds of certain breast cancer patients safely avoid chemotherapy without significantly compromising their long-term outcomes